PLx Pharma   Report issue

For profit Phase 2 Phase 3 Phase 4
Founded: Houston TX United States (2002)
Status: No NME R&D (2002)

Organization Overview

First Clinical Trial
2005
NCT00219700
First Marketed Drug
2013
acetylsalicylic acid (aspirin)
First NDA Approval
None
Last Known Activity
2021

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

PLx Pharma | PLX PHARMA | PLx Pharma Inc.

Active Ingredients

Marketed Drugs (1)

acetylsalicylic acid (aspirin) (2013)

Drugs in Phase 4 Trials (1)

acetylsalicylic acid (aspirin) (8 trials)

Drugs in Phase 3 Trials (1)

Key: PLx Pharma (0) Acquired (1)

pexiganan acetate (2 trials)

Drugs in Phase 2 Trials (2)

ibuprofen (motrin) (1 trial)

naproxen (naprosyn) (2 trials)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Diabetes Mellitus, Type 2 (Phase 3)

Osteoarthritis (Phase 2)

Ulcer (Phase 2)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 13
  • # of Trial APIs: 4